In this study, we review the recent findings regarding the effects of immunotherapy, especially programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) treatment against NAFLD, NASH, or NAFLD-HCC. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatotic liver disease.